Product › Details

Tecentriq®

Products Next higher product group atezolizumab
Period Status 2016-05-19 registration start
Organisation Organisation Roche (Group)
Document Source Roche. (5/19/16). "Press Release: FDA Grants Roche’s Cancer Immunotherapy Tecentriq (atezolizumab) Accelerated Approval for People with a Specific Type of Advanced Bladder Cancer". Basel.
     

   
Record changed: 2019-03-24

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px

More documents for Tecentriq®


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top